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It has long been discovered that human pluripotent cells could be isolated from the blastocyst state of embryos and called human
embryonic stem cells (ESCs). These cells can be adapted and propagated indeﬁnitely in culture in an undiﬀerentiated manner
as well as diﬀerentiated into cell representing the three major germ layers: endoderm, mesoderm, and ectoderm. However, the
derivation of human pluripotent cells from donated embryos is limited and restricted by ethical concerns. Therefore, various
approacheshavebeenexploredandprovedtheirsuccess.Humanpluripotentcellscanalsobederivedexperimentallybythenuclear
reprogramming of somaticcells. These techniques include somaticcell nuclear transfer (SCNT), cell fusion and overexpression of
pluripotent genes.Inthispaper, wediscussthetechnical challengesofthese approachesfornuclearreprogramming,involvingtheir
advantages and limitations.We will also highlight the possible applications of these techniques in the study of stem cell biology.
1.Introduction
Pluripotent cells can give rise to any fetal or adult cell
types, over 200 speciﬁc cell types. Those in contrast to
progenitor cells that are able to diﬀerentiate into a limited
number of cell fates are described as multipotent cells,
such as hematopoietic progenitor cells. The ﬁrst pluripotent
human embryonic stem cells (hESCs) were derived from the
isolation and culturing of the human inner cell mass (ICM)
[1]. The methodology for deriving hESCs has remained
the same as the original protocol for the derivation of
pluripotent mouse ESCs [2]. According to the ﬁrst described
protocolsdetailing the propagationofhESCs, the blastocyst’s
outer trophecodermal layer is ﬁrst removed by immuno-
surgery and the ICM is subsequently plated onto gamma-
irradiated or mitomycin C-treated mouse embryonic ﬁbrob-
lasts (MEFs) in the presence of high serum concentration.
After several days in culture, hESC colonies begin to form
[1, 3]. Undiﬀerentiated colonies of most hESCs show a
compact morphology with a high nucleus-cytoplasm ratio
and retain pluripotent ability in both in vitro and in vivo
experiments. They are able to form embryoid bodies which
lead to spontaneous diﬀerentiation into three embryonic
germ layers [4]. hESCs can also form teratomas when
implanted into SCID mice [5, 6], which reﬂects their in
vivo diﬀerentiation capability. Such teratoma contribute
cellular regions representative of all three embryonic germ
layers, including gut and glandular epithelium (indicative of
endoderm),cartilage,boneandsmoothmuscle(indicativeof
mesoderm), and neural epithelium and embryonic ganglia
(indicative of ectoderm) [1, 3]. However, due to ethical
restrains, cannot be tested in human system. The major limi-
tations of hESC establishment are the availability of donated
IVF embryos and ethical restriction in some countries. This
has brought about the development of alternative nuclear
reprogramming approaches to obtaining human pluripotent
cells that are closely resemble to hESCs. It was long
thought that when cell diﬀerentiates, it loses their plasticity
and permanently inactivated gene that is no longer need.
Recent ﬁndings demonstrated three approaches for nuclear
reprogramming which are, (1) somatic cell nuclear transfer,
(2)cellfusion, and (3)directreprogramming ofsomaticcells2 Stem Cells International
by overexpression of hESC transcription factors. However, to
improve the success rate of derivation of human pluripotent
cells, it is essential to understand the key regulatory network
of pluripotency because this knowledge will improve the
derivation proﬁciency and culture conditions of human
pluripotent cells. Therefore, this paper intend to describe the
basicpluripotencynetworkofhumanpluripotentcellswhich
is followed by the discussion of technical challenges of the
aforementioned reprogramming approaches.
2.Pluripotency: The RegulationMechanisms of
HumanEmbryonic StemCells(hESCs)
Self-renewal of hESCs is regulated by both intrinsic and
extrinsic factors. Intrinsic factors are transcription factors
that are essential for maintaining hESC identity. The best
studied intrinsic factors are OCT4, NANOG and SOX2,
which play essential roles in both mouse and human ESCs.
OCT4, encoded by the POU5F1 locus, is a homeodomain
transcription factor of the POU family. OCT4 is necessary
for pluripotency,as deﬁned by geneknockoutand transgenic
experiments in mice [7]. Knockingdown OCT4 by RNAi
in hESCs forced them to diﬀerentiate into extraembryonic
endoderm lineages [8]. Studies have deﬁned several tar-
get genes of OCT4. Genes dependent on OCT4 activity
for their expression include FGF4 [9], REX1 [10], and
Lefty-1 [11] while human chorionic gonadotropin (HCG) is
repressed by OCT4 activity [12]. Nanog and SOX2 are also
highly expressed in hESCs and dramatically downregulated
upon cell diﬀerentiation [3, 13, 14]. Like OCT4, NANOG
expression appears to be crucial for the maintenance of
ICM and hESCs; removal of NANOG results in ICM
cells adopting a visceral and parietal endoderm fate while
overexpression retards diﬀerentiation of hESCs and forces
the maintenance of undiﬀerentiated phenotype [15]. Similar
to OCT4,SOX2is important to maintain pluripotentstate of
hESCs. The deﬁciency of SOX2 mediated by RNAi is able to
cause hESC diﬀerentiation toward the trophectoderm [13].
The signiﬁcant roles of SOX2 in pluripotency have been
conﬁrmed by the ability to reprogram human ﬁbroblasts to
become pluripotent cells by expression of SOX2 along with
OCT4, KLF4, and c-Myc [16].
Extrinsic factors, such as growth factor signaling path-
ways, are also very important for regulating self-renewal
of hESCs. However, unlike intrinsic factors, the signaling
pathways required for maintaining self-renewal of mouse
and human ESCs seem very diﬀerent. Although both ESCs
were originally isolated and maintained by coculture on
mitotically inactivated MEF feeder cells, they may require
diﬀerent signals from the feeder cells for retaining their
undiﬀerentiation status. Whereas the derivation of mESCs
and their propagation in an undiﬀerentiated state requires
LIF [17], hESC self-renewal requires FGF2 [3]. One possible
reason for this diﬀerence may result from the diﬀerent
growth factor receptor expression proﬁles in mouse and
human ESCs. mESCs express leukemic inhibitory factor
(LIF) receptor/gp130 receptor complexes, which bind LIF
and mediate pluripotency through downstream activation
of STAT3 [18]. In contrast, hESCs do not express LIF
receptors or gp130 receptors [19]. FGF signaling is thought
currently to be the predominant mechanism by which hESC
pluripotency is maintained in culture. It was found that
undiﬀerentiated hESCs express FGFR1, the cognate receptor
for FGF2, more abundantly than diﬀerentiated cells [19].
Other FGFRs, including FGFR2, FGFR3, and FGFR4, also
appear to be enriched in the undiﬀerentiated hESCs [20].
In addition to FGF signaling, activin/nodal pathway also
maintains pluripotency of hESCs through mechanisms in
which FGF2 acts as a competence factor [21]. It is hoped
that, as the diﬀerent mechanisms underlying pluripotency
of hESCs are unrevealed, essential growth factors, cytokines,
and signaling molecules will be discovered, and this could
improvethemaintenance andderivationeﬃciencyofhuman
pluripotent cells in the simpliﬁed, but optimal, systems for
prolonged periods of time.
3.The Birth ofHumanPluripotentEmbryonic
StemCells(hESCs)
In 1998, Thomson et al. reported the ﬁrst establishment of
hESCs from blastocysts of donated IVF embryos [1]. Growth
of hESCs on inactivated MEFs or in the presence of MEF-
conditioned media introduces the potential of transferring
xenobiotic pathogens from the mouse to human tissues.
Thus, later, the derivation of hESC lines using human feeder
and human serum in order to avoid potential contamination
with xenoproteins and xenogenic tissues was reported [22].
These experiments show that new hESC lines can be derived
in the xeno-free system, thus permitting their therapeutic
application in the future. However, it was an issue of
using feeder cells such as the variation of feeder cells, the
inconvenience in large-scale production, and the suspicion
of molecules produced by feeder cells. Signiﬁcant progress
has been made very recently in understanding how to
maintain hESCs in feeder-free environments by virtue of
supplementation by various cytokines, either FGF2 alone
[23] or in combination with either noggin [24]o ra c t i v i n
A[ 25, 26]. To further apply hESC for clinical lines, it is
obviously a priority to eventually reﬁne hESC culture system
in order to reach GMP standard, which is including cul-
ture conditions, physical environment, facility construction,
equipment, and maintenance [27]. One of the key issues
causing hESC technology to be useful for cell and tissue
therapy in human is the histocompatibility [28]. Recent
data support the concept that hESCs and their diﬀerentiated
progeny possess immune-privileged properties, suggesting
thatcellsderivedfromhESCsmayprovideapotentialtoolfor
induction of immunotolerance [29]. However, there are only
few available hESC lines, which are derived as clinical grade
andthereisaconcernoverthegeneticstabilityofhESCsafter
long-term ampliﬁcation in vitro [30]. More importantly, the
ethical debate over the destruction of human embryos has
largely prohibited the derivation of large number of hESC
lines. The discovery of hESCs opened up the possibility for
the applicationofhuman pluripotentcellsin transplantation
therapy, drug screening, and toxicology studies. However,Stem Cells International 3
thepreviouslymentioned obstaclesmustbe overcomebefore
such potential can be realized. In another scenario for which
the term “personalized pluripotent cells” has been coined,
peoplecouldusetheirownsomaticcellstobereprogrammed
back to the pluripotent cell state. The following message
emphasizes on the challenges of the creation of human




When a nucleus from diﬀerentiated somatic cells, such as
skin cells, is transplanted into an enucleated oocyte, nuclear
reprogramming is initiated, leading to the generation of an
entire individual, which is genetically identical clone of the
original somatic cells. Generation of pluripotent cells by
SCNT has been well documented in mouse model [31, 32].
It is noted that the process of SCNT is comprised of multiple
stages and technical demanding. Principle technique of
nuclear transfer involves a somatic donor cell and unfer-
tilized, enucleated oocytes. The nucleus from the somatic
donor cells is transplanted into the enucleated oocytes by
micromanipulator, leading to union of both components.
This reconstructed cell is stimulated to progress embryonic
development.Stimulationcouldbeperformed byeitherelec-
trical pulse or chemical agents [33]. The unifying aspect of
thereprogramming ofsomaticnucleifollowing theirtransfer
into the egg is that the biochemical changes establishing
constrains on genetic potential are reversed. The eﬃciency
of this reversal most probably determines the subsequent
developmental success of the nuclear transfer embryos. It
was realized that nuclear reprogramming by nuclear transfer
to enucleated oocytes is an ineﬃcient process. While there
are sporadic reports of high eﬃciency, the overall rate of
development to oﬀspring is of the order of 1–3% [34]. The
oocytes to use in SCNT could be either in vivo or in vitro
matured cells, but the in vivo matured oocytes seem to give
a better rate of blastocyst development[35]. The explanation
for this event is that oocytes from sexually mature animals
are more developmentally competent because they have a
better supply of factors that will remodel the nucleus when
it is transferred to the nucleus. In addition to the source
of oocytes, the origin of donor cells also aﬀects the quality
of SCNT-derived embryos. The relatively less diﬀerentiated
donor cells result in the better outcome of blastocyst
development when compared to more diﬀerentiated cells
[34]. In addition, the longer culturing of donor cells in vitro
generally causes the decreased development to blastocysts
[36]. The possibility for this reason is that the nuclei from
lessdiﬀerentiated cellsare more plastic and more readily able
to remove and replace proteins that aﬀect transcription than
nuclei of more diﬀerentiated cells. This also correlates with
the progressive stabilization of various repressive chromatin
structures that assembles as development proceeds [37]. In
addition to all those considerations, SCNT-derived embryos
contain maternal mitochondrial DNA (mtDNA) in oocytes.
The mutation of mtDNA could cause cellular dysfunction,
cancer, and diseases [38–40], limiting the potential uses
of pluripotent cells obtained from this imperfect oocytes.
the success of the replacement of mitochondrial genome
in mature non-human primate It was recently reported
[41]. This approach was performed by transferring spindle
chromosomal complex from one egg to an enucleated,
mitochondrial replete egg. The reconstructed oocytes with
the mitochondrial replacement were capable of supporting
normal fertilization, embryo development, and healthy oﬀ-
spring.Eventhistechniqueisskillful;itcouldbesoonapplied
to human oocytes in which mutations of mtDNA are found.
Reprogramming by nuclear transfer technique has not
been extensively demonstrated in human system since the
access to a source of human oocytes is not only a rare
opportunity, but also an ethical concern of the moment
[42].Apartfromlowavailability,thisprocedurealso depends
on voluntary donation of these oocytes and the success
rate of this technique is considerably low [43, 44]. More
recently, somatic nuclei were transplanted into enucleated
zygotes leading to the generation of cloned embryonic
stem cells and mice. In this technique, mouse zygotes were
temporarily arrested in mitosis using drug nocodazole. The
resulting embryos developed into mice, thus supporting
somatic nuclear reprogramming [45]. Application of this
process toward human system may be applicable; however,
recently, the translation of this procedure is restricted in
human. Interspecies cloning, transplanting human somatic
cell nucleusinto enucleatedanimal oocytes,has shed lighton
surmounting the limitation of availability of human oocytes.
In 2007, there was an introduction of controversial proposal
intheUKforpermittingthecreationofinterspeciesembryos
that was hoping to obtain a suﬃcient number of hybrid
hESC lines for research [46]. But this had brought a massive
argument toward the possibility of human clone generation,
and in some countries this option had been completely
banned. Moreover, due to the development of alternative
approaches of nuclear reprogramming, human interspecies
cloning is no longer in focus by scientists.
5.Heterokaryon: The Generationof
Hybrid PluripotentCells
Another method to generate human pluripotent cells is cell
fusionbetweensomaticcellsand hESCs[47]which is leading
tothebirthof“heterokaryon.”Thetermheterokaryonmeans
a cell that contains multiple genetically diﬀerent nuclei. In
contrast to enucleated oocytes, ESC cytoplasm lacks the
ability to reprogram somatic cells, but does the ESC nuclei
[48]. A conceptually related approach to the reprogramming
of somatic cell nuclei after cell fusion is the dominant
genotype/phenotype of hESCs to nuclear reprogram of
somatic cell after hybridization. The hybrid cells established
by cell fusion show remarkably similar characteristics to
hESCs. It was postulated that the cellular contents of hESCs
comprised of reprogramming factors that could inﬂuence
the epigenetic status of the nucleus of somatic cells back
to pluripotent state [49, 50]. These reprogrammed cells
expressedkeypluripotentgenes,Oct4,Sox2,andNanog[47],4 Stem Cells International
and also could generate all three embryonic germlayers both
in vitro and in vivo [51].As thisprocess involvesthefusion of
both somatic and embryonic stem cells, the reprogrammed
cells consist of chromosomal components from both cells. It
was found that neural stem cells were cocultured with ESCs
suggesting that the acquisition of pluripotency by the adult
neuralstemcellsmay bemediated byspontaneouscellfusion
with the pluripotent cells. These cells were found to fuse and
retain both adult markers and pluripotential [52, 53]. The
pluripotency of such a fusion hybrid cell may not be derived
entirely from the somatic genome, as the somatic genome
may be controlled by key regulatory genes of pluripotent cell
genomes.
However,itis challenging thatsince hybridcells originate
from the fusion of somatic cells and hESCs, the repro-
grammed cells contain chromosomal materials from both
cell types as well as the cells exhibit chromosomal tetraploid.
Up to date, there has been no reported of the success to
remove genetic contents of hESCs from the hybrids cells.
It was hoping that if the hESC genomes were successfully
removed from the hESC-somatic cell hybrids, it could be
possible to obtain immune-matched pluripotent cells from
patient’s own cells. The use of hESC cytoplasm nucleated
from the metaphase stage is another possible option [54].
However, with all these possibilities, there is still one note
of caution that has to be seriously taken into account.
Althoughthehybridscouldcontributetoallthreeembryonic
germ layers, further investigations regarding their epigenetic
anomaly are necessary. It needs to be clariﬁed whether
diﬀerentiated progeny from hybrid cells are functional and
do not present any genetic/epigenetic aberrations which
could subsequently result in cell transformation. Finally, the
factors responsible for the regulation of somatic nuclei in
fusion hybrids must be characterized before they ﬁnd their
usefulness in therapeutic approaches.
6.InducedPluripotencyby Transcription
Factors:The Modulationof the Core Gene
RegulatoryNetwork
The breakthrough in iPSC research was due to the initial
cloning experiment of Dolly the sheep [55]. Then, some
studies revealed that reprogramming factors in ovular cyto-
plasm and ESCs are able to induce pluripotency in somatic
cells [56]. In 2007, it was discovered that overexpression of
4 key transcription factors, Oct4, c-Myc, Sox2, and Klf4,
of hESCs could reprogram human ﬁbroblasts to hES-like
cells, called human induced-pluripotent stem cells (hiPSCs)
[16]. The success of iPSCs was conﬁrmed by latter studies
from multiple groups, including a combination of diﬀerent
factors, Nanog and Lin28 [57]. iPSCs have passed the most
stringent examinations for gene expression proﬁle, pluripo-
tency, self-renewal and germ layer diﬀerentiation both in
vitro and in vivo [16, 58], conﬁrming their remarkable
similarity to hESCs. The development of hiPSC technology
and their characteristics have opened for the new hope for
regenerativemedicine.However,therecentreport discovered
thathiPSCsstillretainedepigeneticmemoryoftheorigincell
[59] and this could cause diﬀerentiation propensity of iPSCs
toward the lineage of starting cells. This issue seems to limit
further application of hiPSCs, especially cell-based therapy.
In the past few years, major focuses for the derivation
of human pluripotent stem cells are centered at iPSCs.
Although the process of reprogramming by overexpression
reprogramming factors sounds simple, there are currently
two main problems with the iPSC technology: (1) the
eﬃciency of hiPSC is substantially low which is less than
0.1% of ﬁbroblasts become hiPSCs [16, 58, 60, 61]a n d
(2) the use of virus as a vector can result in the random
integration of viral DNA into the host-cell genome. Com-
pared to other strategies, the use of viral vector, retrovirus,
a n dl e n t i v i r u si sc o n s i d e r e da sah i g h - e ﬃcient tool for
gene transfer; thus, viral transfection is becoming the most
popular choice for the expression of pluripotency-inducing
transgenes [16]. However, the transfer of reprogramming
genes by viral vectors appears to be a disadvantage of
iPSCs in human clinical setting, such as transplantation,
because the integration of viral DNA into the host-cell
genome could alter the normality of host-cell genome and
lead to cell transformation [62]. There are many studies to
ﬁnd alternatives to using viral vectors for reprogramming
somatic cells. These techniques include the use of plasmid
transfection and the piggyBac transposition system [63].
An alternative non-viral vector transfection method is
using a single multiprotein expression vector comprised of
coding sequences of c-Myc, Klf4, Oct4, and Sox2 linked
with 2A peptides to reprogram both mouse and human
ﬁbroblasts [61]. Once reprogramming was achieved, the
transgene could be removed using transient Cre expression.
The piggyBac system is a transposon to deliver genes in
mammalian cells. The piggyBacsystem is ableto deliverlarge
genetic elements without signiﬁcant reduction in eﬃciency.
This system was used to reprogram human ﬁbroblasts to
iPSCs [60]. Studiesalso explored the applicationof modiﬁed
mRNAandproteins,encodedbythosereprogramming genes
[64, 65] and showed the success of reprogramming process
by using these molecules. Nevertheless, compared to viral
vectors, the proﬁciency of these alternatives signiﬁcantly
reduced the number of reprogrammed cells and the pro-
duction of these reprogramming molecules requires speciﬁc
laboratories. Despite many challenges, there are potentially
multiple advantages of hiPSCs over hESCs, as the former
can be generated from individual, maintaining one’s genetic
constitution and identity. In addition, iPSCs represent a
source of diﬀerentiated cell types genetically identical to the
person of origin that may be useful for screening drugs for
individual forms of pathology and for being a source of
transplantable tissues.
7.FutureChallenges
Itis along andamusing history ofnuclear reprogramming in
which increasingly sophisticated technologies have became
accessible. A comparison of pluripotent cells derived from
these three diﬀerent approaches exhibits certain common
properties, including gene expression proﬁle and diﬀeren-
tiation capability. In addition, the elongation of telomereStem Cells International 5
and reactivation of human telomerase reverse transcriptase
are commonly found in these reprogrammed cells. However,
for all nuclear reprogramming strategies, some somatic
cells are more readily reprogrammed than others. Thus,
these features can be diﬀerentially exploited to investigate
the principle mechanisms underlying pluripotency. Each
of the three approaches is distinct and has its own pros
and cons. For instance, SCNT is characterized by rapid
reprogramming process [66] and is ideally appropriated to
elucidating the fundamental principles of early embryonic
development and reproductive biology, as well as yielding
as u ﬃcient number of hESCs for therapeutic purposes. In
contrary, cell fusion is technically simple. When cell fusion
is used to form mixed-species heterokaryons, which do not
proliferate, pluripotency genes is activated quickly and with
high eﬃciency [67]. This approach is therefore particularly
well suited to demonstrating molecular mechanisms that
control the onset of nuclear reprogramming, but it does
not yield clinical grade cells. On the other hand, forced
expression of pluripotenttranscription factors could provide
such cells. Due to the ease of iPSC technology, it is now
worldwide studied in laboratories all over the world. In
addition, iPSCs oﬀer a tool to study human diseases [68]
and drug discovery [69]. In the near future, it is much
possible that the novel approach of nuclear reprogramming
willemergewhichcouldpresentasthesaferstrategyandwith
higher eﬃciency than those currently available.
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